tert-butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate | 1253909-60-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: tert-butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate
• 英文别名: tert-butyl 2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]butanoate
• CAS: 1253909-60-2
• 化学式: C₂₈H₄₆O₃
• 分子量: 430.671
• InChiKey: CHSHEVONIHVWMM-QXPWYRSVSA-N

物化性质

• 沸点：
  501.4±50.0 °C(Predicted)
• 密度：
  0.918±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  31
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate 以71的产率得到2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yl)oxy)butanoic acid
  参考文献：
  名称：

  [EN] SALICYLATE FATTY ACID DERIVATIVES
  [FR] DÉRIVÉS SALICYLATES ACIDE GRAS

  摘要：

  本文揭示了水杨酸衍生物的脂肪酸共轭物及其组合物。此外，还揭示了治疗和/或预防炎症性疾病，包括炎症和/或炎症性肠病（IBD）、血脂异常，包括混合型血脂异常和/或高甘油三酯血症、高血脂，例如三酰甘油和/或胆固醇、代谢综合征、外周胰岛素抵抗、糖尿病、动脉硬化的方法；一种降低非HDL胆固醇的方法；以及一种提高HDL胆固醇的方法，包括根据本公开的至少一种化合物的有效剂量的给药。

  公开号：

  WO2011089529A1
• 作为产物：
  描述：

  2-溴丁酸叔丁酯 、 (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol 在 四丁基氯化铵 、 sodium hydroxide 作用下， 以 水 、 甲苯 为溶剂， 反应 12.0h， 以36%的产率得到tert-butyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoate
  参考文献：
  名称：

  [EN] USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3
  [FR] UTILISATION DE COMPOSÉS THIA OXO POUR LA RÉDUCTION DE L'APO C3

  摘要：

  公开了一种减少需要的主体中的载脂蛋白C-III（apoC-III）mRNA或蛋白质的方法，包括向其投予公式（I）的化合物的药效有效量，或其药效可接受的盐或酯，其中R1和R2分别选择自氢原子或线性、支链和/或环状的C1-C6烷基基团，但R1和R2不能同时为氢。

  公开号：

  WO2016156912A1

文献信息

• [EN] FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS<br/>[FR] DÉRIVÉS D'ACIDE GRAS POUR LE TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE
  申请人：BASF AS

  公开号：WO2019111048A1

  公开（公告）日：2019-06-13

  The present disclosure provides a compound for use in therapeutic and/or prophylactic treatment of non-alcoholic steatohepatitis (NASH) and/or alcoholic steatohepatitis (ASH). The compound for use according to the invention, is an unsaturated fatty acid with an oxygen incorporated in the β-position, and further comprising an α-substituent. More particularly, the invention provides a compound for use in treatment of NASH and/or ASH, and a method using this, wherein the compound is of Formula (II), wherein R1, R2, R3, X, and Y are as defined in the specification; and wherein this compound may be administered alone or in combination with an additional active agent.

  本公开提供了一种用于治疗和/或预防非酒精性脂肪肝炎（NASH）和/或酒精性脂肪肝炎（ASH）的化合物。根据本发明使用的化合物是一种在β位含有氧原子的不饱和脂肪酸，并且还包含一个α-取代基。更具体地说，本发明提供了一种用于治疗NASH和/或ASH的化合物以及使用该方法，其中该化合物是公式（II），其中R1、R2、R3、X和Y如说明书中所定义；并且该化合物可以单独使用或与另一种活性剂结合使用。
• [EN] LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE<br/>[FR] COMPOSÉS LIPIDIQUES ET COMPOSITIONS ASSOCIÉES ET LEUR UTILISATION OPHTALMIQUE
  申请人：BIOZEP AS

  公开号：WO2017093732A1

  公开（公告）日：2017-06-08

  The invention relates to lipid compounds of formula (I) and their pharmaceutically acceptable salts for the prevention and/or treatment of ophthalmic disorders such as retinal degenerative disorders and ocular inflammatory diseases: (I) (wherein R1 is either a C9 to C22 alkyl group, or a C9 to C22 alkenyl group having from 1 to 6 double bonds; R2 is selected from the group consisting of a halogen atom, a hydroxy group, an alkyl group, an alkoxy group, an alkylthio group, a carboxy group, an acyl group, an amino group, and an alkylamino group; R3 is a hydrogen atom, or a group R2; R4 is a carboxylic acid or a derivative thereof; and X is methylene (-CH2-), or an oxygen or sulfur atom).

  本发明涉及用于预防或治疗如视网膜退行性疾病和眼部炎症疾病的眼科疾病的一类脂质化合物公式(I)及其药用可接受盐：(I)（其中R1为C9至C22的烷基或具有1至6个双键的C9至C22的烯基；R2选自卤素原子、羟基、烷基、烷氧基、烷硫基、羧基、酰基、氨基和烷基氨基的组；R3为氢原子或R2基团；R4为羧酸或其衍生物；X为亚甲基(-CH2-)，或氧或硫原子）。
• [EN] METHODS OF TREATMENT USING LIPID COMPOUNDS<br/>[FR] MÉTHODES DE TRAITEMENT AU MOYEN DE COMPOSÉS LIPIDIQUES
  申请人：PRONOVA BIOPHARMA NORGE AS

  公开号：WO2012059818A1

  公开（公告）日：2012-05-10

  Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): (I) or a pharmaceutically acceptable salt, or ester thereof, wherein R1 and R2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C1-C6 alkyl groups, with the proviso that R1 and R2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL- cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

  本文揭示了一种治疗或预防患者需要的至少一种疾病或病况的方法，包括给予化合物Formula (I)：(I)或其药学上可接受的盐或酯，其中R1和R2分别选择自氢原子或线性、支链和/或环状的C1-C6烷基基团，但R1和R2不能同时为氢或其药学上可接受的盐或酯。这些疾病或病况可能涉及冠心病（CHD），例如动脉粥样硬化；代谢综合征/胰岛素抵抗；以及脂质代谢异常症状，如高三酸甘油酯（HTG）、升高的LDL-胆固醇、升高的总胆固醇、升高的载脂蛋白B和低HDL-胆固醇。本公开还提供了一种减少动脉粥样硬化发展的方法。还公开了包含化合物Formula (I)的药物组合物。
• Novel lipid compounds
  申请人：Pronova BioPharma Norge AS

  公开号：EP2248798A1

  公开（公告）日：2010-11-10

  The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same or different and may be selected from a group of different substituents; and X represents a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式（I）的脂质化合物：其中R1选择自C10-C22烷基，具有1-6个双键的C10-C22烯基和具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基组成；X代表羧酸或其衍生物，如羧酸酯，羧酸酐或羧酰胺；或其药学上可接受的盐，溶剂化物，该盐的溶剂化物或其前药。本发明还涉及包含这些化合物的制药组合物和脂质组合物，以及将这些化合物用作药物或用于治疗，特别是用于治疗与心血管，代谢和炎症相关的疾病。
• POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS
  申请人：Hovland Ragnar

  公开号：US20120122940A1

  公开（公告）日：2012-05-17

  The present disclosure relates to lipid compounds of the general formula (I): R1-O—C(R2)(R3)-X  (I) wherein R 1 is a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, or a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

  本公开涉及一般式（I）的脂质化合物：R1-O-C（R2）（R3）-X（I），其中R1是C10-C22烷基，具有1-6个双键的C10-C22烯基，或具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基；X是羧酸或其衍生物，例如羧酸酯，羧酸酐，磷脂，甘油三酯或羧酰胺；或药学上可接受的盐，溶剂，该盐的溶剂或其前药。本公开还涉及包含至少一种根据本公开的化合物的制药组合物和脂质组合物，并涉及这些化合物的用途作为药物或用于治疗，特别是用于治疗与心血管，代谢和炎症相关的疾病领域。